Literature DB >> 25400013

Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.

Reza Sadjadi1, Mary M Reilly, Michael E Shy, Davide Pareyson, Matilde Laura, Sinead Murphy, Shawna M E Feely, Tiffany Grider, Chelsea Bacon, Giuseppe Piscosquito, Daniela Calabrese, Ted M Burns.   

Abstract

Charcot-Marie-Tooth Neuropathy Score second version (CMTNSv2) is a validated clinical outcome measure developed for use in clinical trials to monitor disease impairment and progression in affected CMT patients. Currently, all items of CMTNSv2 have identical contribution to the total score. We used Rasch analysis to further explore psychometric properties of CMTNSv2, and in particular, category response functioning, and their weight on the overall disease progression. Weighted category responses represent a more accurate estimate of actual values measuring disease severity and therefore could potentially be used in improving the current version.
© 2014 Peripheral Nerve Society.

Entities:  

Keywords:  Charcot-Marie-Tooth; Charcot-Marie-Tooth Neuropathy Score (CMTNS2) second version; Rasch analysis; outcome measures; psychometrics

Mesh：

Year:  2014        PMID： 25400013      PMCID： PMC4303498          DOI： 10.1111/jns.12084

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN： 1085-9489            Impact factor:   3.494


  13 in total

1.  168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT).

Authors:  M M Reilly; M E Shy; F Muntoni; D Pareyson
Journal:  Neuromuscul Disord       Date:  2010-09-17       Impact factor: 4.296

Review 2.  Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations.

Authors:  Jeremy C Hobart; Stefan J Cano; John P Zajicek; Alan J Thompson
Journal:  Lancet Neurol       Date:  2007-12       Impact factor: 44.182

3.  Watch out, watch out, the FDA are about.

Authors:  Stefan J Cano; Jeremy C Hobart
Journal:  Dev Med Child Neurol       Date:  2008-06       Impact factor: 5.449

4.  High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.

Authors:  Richard A Lewis; Michael P McDermott; David N Herrmann; Ahmet Hoke; Lora L Clawson; Carly Siskind; Shawna M E Feely; Lindsey J Miller; Richard J Barohn; Patricia Smith; Elizabeth Luebbe; Xingyao Wu; Michael E Shy
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

5.  Total neuropathy score: validation and reliability study.

Authors:  D R Cornblath; V Chaudhry; K Carter; D Lee; M Seysedadr; M Miernicki; T Joh
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

6.  CMT1X phenotypes represent loss of GJB1 gene function.

Authors:  M E Shy; C Siskind; E R Swan; K M Krajewski; T Doherty; D R Fuerst; P J Ainsworth; R A Lewis; S S Scherer; A F Hahn
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

7.  The importance of patient-reported outcomes...it's all about the patients.

Authors:  Linda Bren
Journal:  FDA Consum       Date:  2006 Nov-Dec

8.  Neuropathy progression in Charcot-Marie-Tooth disease type 1A.

Authors:  M E Shy; L Chen; E R Swan; R Taube; K M Krajewski; D Herrmann; R A Lewis; M P McDermott
Journal:  Neurology       Date:  2008-01-29       Impact factor: 9.910

9.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

10.  Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Authors:  Davide Pareyson; Mary M Reilly; Angelo Schenone; Gian Maria Fabrizi; Tiziana Cavallaro; Lucio Santoro; Giuseppe Vita; Aldo Quattrone; Luca Padua; Franco Gemignani; Francesco Visioli; Matilde Laurà; Davide Radice; Daniela Calabrese; Richard A C Hughes; Alessandra Solari
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182
View more
  25 in total

1.  Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.

Authors:  Ellen M Lavoie Smith; Noah Zanville; Grace Kanzawa-Lee; Clare Donohoe; Celia Bridges; Charles Loprinzi; Jennifer Le-Rademacher; James J Yang
Journal:  Support Care Cancer       Date:  2018-11-20       Impact factor: 3.603

2.  Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.

Authors:  John Svaren; John J Moran; Xingyao Wu; Riccardo Zuccarino; Chelsea Bacon; Yunhong Bai; Raghu Ramesh; Laurie Gutmann; Daniel M Anderson; Derek Pavelec; Michael E Shy
Journal:  Ann Neurol       Date:  2019-04-22       Impact factor: 10.422

3.  Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.

Authors:  Melissa R Mandarakas; Manoj P Menezes; Kristy J Rose; Rosemary Shy; Kate Eichinger; Maria Foscan; Timothy Estilow; Rachel Kennedy; Karen Herbert; Paula Bray; Kathryn Refshauge; Monique M Ryan; Eppie M Yiu; Michelle Farrar; Hugo Sampaio; Isabella Moroni; Emanuela Pagliano; Davide Pareyson; Sabrina W Yum; David N Herrmann; Gyula Acsadi; Michael E Shy; Joshua Burns; Oranee Sanmaneechai
Journal:  Brain       Date:  2018-12-01       Impact factor: 13.501

Review 4.  Mechanisms and Treatments in Demyelinating CMT.

Authors:  Vera Fridman; Mario A Saporta
Journal:  Neurotherapeutics       Date:  2021-11-08       Impact factor: 6.088

5.  A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.

Authors:  Vera Fridman; Stefan Sillau; Gyula Acsadi; Chelsea Bacon; Kimberly Dooley; Joshua Burns; John Day; Shawna Feely; Richard S Finkel; Tiffany Grider; Laurie Gutmann; David N Herrmann; Callyn A Kirk; Sarrah A Knause; Matilde Laurá; Richard A Lewis; Jun Li; Thomas E Lloyd; Isabella Moroni; Francesco Muntoni; Emanuela Pagliano; Chiara Pisciotta; Giuseppe Piscosquito; Sindhu Ramchandren; Mario Saporta; Reza Sadjadi; Rosemary R Shy; Carly E Siskind; Charlotte J Sumner; David Walk; Janel Wilcox; Sabrina W Yum; Stephan Züchner; Steven S Scherer; Davide Pareyson; Mary M Reilly; Michael E Shy
Journal:  Neurology       Date:  2020-02-11       Impact factor: 9.910

6.  The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).

Authors:  Katy Eichinger; Joshua Burns; Kayla Cornett; Chelsea Bacon; Mary Lohse Shepherd; Joan Mountain; Janet Sowden; Rosemary Shy; Michael E Shy; David N Herrmann
Journal:  Neurology       Date:  2018-09-19       Impact factor: 9.910

7.  MicroRNAs as Biomarkers of Charcot-Marie-Tooth Disease Type 1A.

Authors:  Hongge Wang; Matthew Davison; Kathryn Wang; Tai-He Xia; Katherine M Call; Jun Luo; Xingyao Wu; Riccardo Zuccarino; Alexa Bacha; Yunhong Bai; Laurie Gutmann; Shawna M E Feely; Tiffany Grider; Alexander M Rossor; Mary M Reilly; Michael E Shy; John Svaren
Journal:  Neurology       Date:  2021-05-24       Impact factor: 11.800

8.  CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.

Authors:  V Fridman; B Bundy; M M Reilly; D Pareyson; C Bacon; J Burns; J Day; S Feely; R S Finkel; T Grider; C A Kirk; D N Herrmann; M Laurá; J Li; T Lloyd; C J Sumner; F Muntoni; G Piscosquito; S Ramchandren; R Shy; C E Siskind; S W Yum; I Moroni; E Pagliano; S Zuchner; S S Scherer; M E Shy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-11-27       Impact factor: 10.154

9.  A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.

Authors:  Jonas Mandel; Viviane Bertrand; Philippe Lehert; Shahram Attarian; Laurent Magy; Joëlle Micallef; Ilya Chumakov; Catherine Scart-Grès; Mickael Guedj; Daniel Cohen
Journal:  Orphanet J Rare Dis       Date:  2015-06-13       Impact factor: 4.123

Review 10.  Recent advances in the genetic neuropathies.

Authors:  Alexander M Rossor; Pedro J Tomaselli; Mary M Reilly
Journal:  Curr Opin Neurol       Date:  2016-10       Impact factor: 5.710
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.